Pfizer’s Estimates Raised at Goldman Sachs (PFE)

By Staff,

Shutterstock photo

Pharmaceuticals maker Pfizer Inc. ( PFE ) on Monday saw its earnings estimates lifted by analysts at Goldman Sachs.

The firm said it boosted its estimates for PFE through 2015, noting that new products should help drive earnings growth. The firm maintained its "Buy" rating and $22 price target on PFE, suggesting a 21% upside to the stock's Friday closing price of $18.21.

Pfizer shares rose 54 cents, or +3%, in premarket trading Monday.

The Bottom Line
Shares of Pfizer ( PFE ) have a 4.39% dividend yield, based on Friday's closing stock price of $18.21. The stock has technical support in the $16-$17 price area. If the shares can firm up, we see overhead resistance around the $20 price level.

Pfizer Inc. ( PFE ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by

This article appears in: Investing Stocks
Referenced Stocks: PFE

More from

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by